Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre‐eclampsia
Ultrasound in Obstetrics & Gynecology · 2025
DOI: 10.1002/uog.70129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ultrasound in Obstetrics & Gynecology, 2025. Verfasst von P Palmrich und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Feto-Maternal Medicine, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Natriuretic Peptide, Brain, Pre-Eclampsia, Peptide Fragments. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), a marker of cardiac stress, has been proposed as a potential prognostic biomarker for maternal adverse outcome in pre‐eclampsia (PE). This study aimed to evaluate the predictive value of NT‐proBNP for severe maternal adverse outcome in pregnancies with an established diagnosis of PE.
Methods
This was a retrospective cohort study of singleton pregnancies diagnosed with PE ≤ 36 weeks of gestation that were assessed at the Medical University of Vienna between January 2018 and December 2023. Maternal serum levels of NT‐proBNP, soluble fms‐like tyrosine kinase‐1 (sFlt‐1) and placental growth factor (PlGF) were measured at the time of PE diagnosis. The primary outcome was the occurrence of a severe maternal adverse event, including intensive care unit admission, maternal death, pulmonary edema and severe neurological complications. Associations between severe maternal adverse outcome and Z ‐scores for NT‐proBNP and the sFlt‐1/PlGF ratio were analyzed using logistic and Cox regression models adjusted for gestational age at sampling and the Z ‐score of the other biomarker. The area under the receiver‐operating‐characteristics (ROC) curve (AUC) was used to assess the discriminative ability of the biomarkers.
Results
Of 130 women included in our cohort, 13 (10%) experienced severe maternal adverse outcome. NT‐proBNP levels were significantly higher in this group (median, 688.0 (interquartile range (IQR), 249.6–1038.0) pg/mL vs 106.1 (IQR, 50.6–280.6) pg/mL; P < 0.001). Higher NT‐proBNP Z ‐score was associated significantly with severe maternal adverse outcome (adjusted odds ratio, 3.24 (95% CI, 1.50–7.84); P = 0.005) and predicted shorter time‐to‐delivery with severe maternal adverse outcome (adjusted hazard ratio, 3.08 (95% CI, 1.47–6.44); P = 0.003) after adjusting for gestational age at sampling and sFlt‐1/PlGF ratio Z ‐score. The sFlt‐1/PlGF ratio was not associated significantly with these outcomes. ROC‐curve analysis showed that NT‐proBNP had superior discriminative performance compared with the sFlt‐1/PlGF ratio (AUC, 0.75 (95% CI, 0.61–0.90) vs 0.67 (95% CI, 0.56–0.79)). The performance of both biomarkers improved when combined with gestational age at sampling (AUC, 0.82 (95% CI, 0.71–0.94) vs 0.76 (95% CI, 0.65–0.88)).
Conclusion
NT‐proBNP was a strong predictor of severe maternal adverse outcome and time‐to‐delivery in women diagnosed with PE, especially in early‐onset cases. NT‐proBNP may serve as a clinically accessible biomarker for risk stratification and surveillance in women with established PE. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Feto-Maternal Medicine, Medical University of Vienna, Vienna, Austria.
- Department of Obstetrics and Gynecology, Koc University Hospital, Istanbul, Turkey.
ORCID-Profile: P Palmrich, E Kalafat, C Haberl, J Binder
Zitieren
APA
Palmrich, P., Kalafat, E., Schirwani-Hartl, N., Haberl, C., Dorittke, T., Steinmetz, L., Krepler, L., & Binder, J. (2025). Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre‐eclampsia. Ultrasound in Obstetrics & Gynecology. https://doi.org/10.1002/uog.70129
Vancouver
Palmrich P, Kalafat E, Schirwani-Hartl N, Haberl C, Dorittke T, Steinmetz L, et al. Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre‐eclampsia. Ultrasound in Obstetrics & Gynecology. 2025. doi:10.1002/uog.70129
BibTeX
@article{Palmrich2025,
author = {Palmrich, P and Kalafat, E and Schirwani-Hartl, N and Haberl, C and Dorittke, T and Steinmetz, L and Krepler, L and Binder, J},
title = {Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre‐eclampsia},
journal = {Ultrasound in Obstetrics & Gynecology},
year = {2025},
doi = {10.1002/uog.70129}
}
EUVIMED